Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy.
Nanoclay can be incorporated into emerging dual functional drug delivery systems (DDSs) to promote efficiency in drug delivery and reduce the toxicity of doxorubicin (DOX) used for thyroid cancer treatment. This paper reports the expansion of the basal spacing of kaolinite nanoclay was expanded from 0.72 nm to 0.85 nm, which could provide sufficiently spacious site for hosting doxorubicin molecules and controlling the diffusion rate. A targeted design for papillary thyroid cancer cells was achieved by introducing KI, which is consumed by the sodium-iodide symporter (NIS). As indicated by MTT assays, confocal laser scanning microscopy and bio-TEM observations, methoxy-intercalated kaolinite (KaolinMeOH) exhibited negligible cytotoxicity against papillary thyroid cancer cells. By contrast, DOX-KaolinMeOH showed dose-dependent therapeutic effects in vitro, and KI@DOX-KaolinMeOH was found to act as a powerful targeted therapeutic drug. Furthermore, active and passive targeting strategies played a role in the accumulation of the drug molecules, as verified by an in vivo bio-distribution analysis.
Centre for Mineral Materials, School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China.
Yi
Y
Zhang
Centre for Mineral Materials, School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China.
Mei
M
Long
Xiangya Hospital, Central South University, Changsha 410078, China.
Peng
P
Huang
Centre for Mineral Materials, School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China.|Hunan Key Lab of Mineral Materials and Application, Central South University, Changsha 410083, China.|State Key Lab of Powder Metallurgy, Central South University, Changsha 410083, China.
Huaming
H
Yang
Xiangya Hospital, Central South University, Changsha 410078, China.
Shi
S
Chang
Centre for Mineral Materials, School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China.|Hunan Key Lab of Mineral Materials and Application, Central South University, Changsha 410083, China.
Yuehua
Y
Hu
School of Chemistry and Chemical Engineering, Central South University, Changsha 410083, China.
Aidong
A
Tang
Xiangya Hospital, Central South University, Changsha 410078, China.
Linfeng
L
Mao
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D004337:Drug Carriers / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007616:Kaolin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D049329:Nanostructures / Q000633:toxicity; D011817:Rabbits; D013552:Swine; D013556:Swine, Miniature; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D014018:Tissue Distribution
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D007616:Kaolin; D004317:Doxorubicin